Xuan Zhu Bio-B Opens 153.97% Higher on Debut as Innovative Drugmaker Sees Value Reassessment

Today, the highly anticipated Xuan Zhu Bio-B (02575) commenced trading on the Hong Kong Stock Exchange. By the close of morning trading, the stock had surged 153.97% from its issue price of HK$11.60 to HK$29.46, with turnover reaching HK$257 million, reflecting sustained investor enthusiasm for the innovative pharmaceutical sector.

According to the listing prospectus, Xuan Zhu Bio-Pharma issued 67.3335 million H-shares globally at HK$11.60 per share, raising net proceeds of approximately HK$701 million. With a lot size of 500 shares, each lot recorded an unrealised profit exceeding HK$8,900 during morning trading, excluding brokerage fees.

Public records indicate Xuan Zhu Biotech is an innovation-driven Chinese biopharmaceutical enterprise. Following its majority acquisition by Sihuan Pharmaceutical Holdings Group (0460.HK) in 2008, the company has established a comprehensive in-house R&D platform. Its pipeline exhibits a robust tiered structure, covering key therapeutic areas including gastrointestinal disorders, oncology, and non-alcoholic steatohepatitis (NASH).

As of the latest data, the company holds over ten drug assets in development, including three assets with New Drug Application (NDA) approvals, one project in the NDA registration phase, one in Phase III clinical trials, four in Phase I clinical trials, and five with Investigational New Drug (IND) approvals.

The company currently holds NDA approvals for three core products: KBP-3571 (an innovative proton pump inhibitor (PPI) for treating gastrointestinal disorders); XZP-3287 (a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor targeting breast cancer); XZP-3621 (an anaplastic lymphoma kinase (ALK) inhibitor targeting non-small cell lung cancer (NSCLC)). This pipeline design reflects the company's strategic approach to balancing development risks with innovation investment. By generating stable cash flow from commercialised or late-stage assets, the company can sustainably support the research and development of early-stage innovative drugs, creating a virtuous cycle.

Xuan Zhu Biotech's robust debut performance continues the favourable momentum seen in recent Hong Kong biotech IPOs. Following reforms to the Hong Kong IPO pricing mechanism, new listings generally demonstrate strong first-day performance, with the biotech sector particularly attracting capital inflows.

However, investors should note that the company remains in a phase of significant R&D expenditure, with sustained profitability still some way off. Financial data indicates net losses of RMB 300 million, RMB 556 million, and RMB 111 million for 2023, 2024, and the first half of 2025 respectively. For the full year 2024, the company reported operating revenue of RMB 30.09 million.

For biotech enterprises, the initial public offering day merely marks the commencement of scrutiny by capital markets. Investors should maintain vigilance regarding the market access progress of core products, commercialisation scale-up, and the advancement efficiency of subsequent R&D pipelines. Against the backdrop of both the Hang Seng Biotech Index and the Innovative Drug Index undergoing adjustment phases, whether Xuan Zhu Biotech can achieve sustained value growth through product advantages will be the pivotal determinant of its secondary market performance.

Disclaimer: The content herein is for reference only and does not constitute any form of investment advice. Should any information contained herein prove inaccurate, incomplete, or potentially misleading, please refer to the company's official announcements. Market risks exist; investment requires caution.